GB201208293D0 - Hydrochlorice salt of peptide - Google Patents

Hydrochlorice salt of peptide

Info

Publication number
GB201208293D0
GB201208293D0 GB201208293A GB201208293A GB201208293D0 GB 201208293 D0 GB201208293 D0 GB 201208293D0 GB 201208293 A GB201208293 A GB 201208293A GB 201208293 A GB201208293 A GB 201208293A GB 201208293 D0 GB201208293 D0 GB 201208293D0
Authority
GB
United Kingdom
Prior art keywords
hydrochlorice
peptide
salt
hydrochlorice salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201208293A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Niox Healthcare Ltd
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circassia Ltd filed Critical Circassia Ltd
Priority to GB201208293A priority Critical patent/GB201208293D0/en
Publication of GB201208293D0 publication Critical patent/GB201208293D0/en
Priority to HK15102275.5A priority patent/HK1201850A1/xx
Priority to CA 2873120 priority patent/CA2873120A1/en
Priority to AU2013257784A priority patent/AU2013257784A1/en
Priority to CN201380036507.6A priority patent/CN104428311B/zh
Priority to SG11201407446TA priority patent/SG11201407446TA/en
Priority to MX2014013394A priority patent/MX2014013394A/es
Priority to JP2015510875A priority patent/JP5982562B2/ja
Priority to IN9367DEN2014 priority patent/IN2014DN09367A/en
Priority to EP13722023.2A priority patent/EP2847209B8/en
Priority to PCT/GB2013/051201 priority patent/WO2013167897A1/en
Priority to GB201421491A priority patent/GB2517354A/en
Priority to BR112014028130A priority patent/BR112014028130A2/pt
Priority to KR20147034734A priority patent/KR20150014955A/ko
Priority to EA201492068A priority patent/EA201492068A1/ru
Priority to US14/400,052 priority patent/US9657061B2/en
Priority to IL235388A priority patent/IL235388A/en
Priority to ZA2014/08290A priority patent/ZA201408290B/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
GB201208293A 2012-05-11 2012-05-11 Hydrochlorice salt of peptide Ceased GB201208293D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GB201208293A GB201208293D0 (en) 2012-05-11 2012-05-11 Hydrochlorice salt of peptide
US14/400,052 US9657061B2 (en) 2012-05-11 2013-05-09 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
IN9367DEN2014 IN2014DN09367A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-05-11 2013-05-09
PCT/GB2013/051201 WO2013167897A1 (en) 2012-05-11 2013-05-09 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
AU2013257784A AU2013257784A1 (en) 2012-05-11 2013-05-09 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
CN201380036507.6A CN104428311B (zh) 2012-05-11 2013-05-09 肽的盐酸化物盐以及其与其他肽组合用于免疫疗法的用途
SG11201407446TA SG11201407446TA (en) 2012-05-11 2013-05-09 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
MX2014013394A MX2014013394A (es) 2012-05-11 2013-05-09 Sal de clorhidrato de un peptido y su uso en combinacion con otros peptidos para inmunoterapia.
JP2015510875A JP5982562B2 (ja) 2012-05-11 2013-05-09 ペプチドの塩酸塩及び他のペプチドとの併用によるその免疫治療用途
HK15102275.5A HK1201850A1 (en) 2012-05-11 2013-05-09 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
EP13722023.2A EP2847209B8 (en) 2012-05-11 2013-05-09 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
CA 2873120 CA2873120A1 (en) 2012-05-11 2013-05-09 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
GB201421491A GB2517354A (en) 2012-05-11 2013-05-09 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
BR112014028130A BR112014028130A2 (pt) 2012-05-11 2013-05-09 Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
KR20147034734A KR20150014955A (ko) 2012-05-11 2013-05-09 펩티드의 히드로클로라이드 염 및 다른 펩티드와 조합한 그의 면역요법을 위한 용도
EA201492068A EA201492068A1 (ru) 2012-05-11 2013-05-09 Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии
IL235388A IL235388A (en) 2012-05-11 2014-10-29 Peptide hydrochloride salt and its use in combination with other immunotherapy peptides
ZA2014/08290A ZA201408290B (en) 2012-05-11 2014-11-12 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201208293A GB201208293D0 (en) 2012-05-11 2012-05-11 Hydrochlorice salt of peptide

Publications (1)

Publication Number Publication Date
GB201208293D0 true GB201208293D0 (en) 2012-06-20

Family

ID=46396890

Family Applications (2)

Application Number Title Priority Date Filing Date
GB201208293A Ceased GB201208293D0 (en) 2012-05-11 2012-05-11 Hydrochlorice salt of peptide
GB201421491A Withdrawn GB2517354A (en) 2012-05-11 2013-05-09 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB201421491A Withdrawn GB2517354A (en) 2012-05-11 2013-05-09 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy

Country Status (17)

Country Link
US (1) US9657061B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2847209B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP5982562B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20150014955A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104428311B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013257784A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014028130A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2873120A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA201492068A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (2) GB201208293D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1201850A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL235388A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN09367A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2014013394A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201407446TA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013167897A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201408290B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MY199068A (en) 2014-12-23 2023-10-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
ES2991207T3 (es) 2015-03-27 2024-12-02 Immatics Biotechnologies Gmbh Péptidos novedosos y combinación de péptidos para su uso en inmunoterapia contra diversos tumores (SEQ ID 253 - Rad54b)
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
TWI792442B (zh) * 2021-07-23 2023-02-11 建誼生技股份有限公司 依特卡肽鹽酸鹽之製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4874522B2 (ja) * 2001-12-05 2012-02-15 サーカッシア リミテッド 免疫療法および系
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
EP2397154B1 (en) * 2007-08-15 2015-07-15 Circassia Limited Peptides for desensibilization against allergens
GB2455108A (en) * 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
BR112012025047A2 (pt) * 2010-03-31 2016-06-21 Stabilitech Ltd formulações líquidas estabilizadas

Also Published As

Publication number Publication date
SG11201407446TA (en) 2015-03-30
MX2014013394A (es) 2015-02-04
US20150110820A1 (en) 2015-04-23
WO2013167897A1 (en) 2013-11-14
EA201492068A1 (ru) 2015-03-31
JP5982562B2 (ja) 2016-08-31
EP2847209B8 (en) 2020-10-07
GB2517354A (en) 2015-02-18
EP2847209A1 (en) 2015-03-18
IN2014DN09367A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-07-17
GB201421491D0 (en) 2015-01-14
JP2015517484A (ja) 2015-06-22
US9657061B2 (en) 2017-05-23
CA2873120A1 (en) 2013-11-14
CN104428311A (zh) 2015-03-18
CN104428311B (zh) 2019-11-01
IL235388A (en) 2016-06-30
EP2847209B1 (en) 2020-08-05
KR20150014955A (ko) 2015-02-09
BR112014028130A2 (pt) 2017-08-15
AU2013257784A1 (en) 2014-11-20
ZA201408290B (en) 2016-01-27
HK1201850A1 (en) 2015-09-11

Similar Documents

Publication Publication Date Title
IL273276A (en) salt crystals
ZA201401268B (en) Noribogaine salt ansolvates
IL232599A (en) Hydrobromide salt of peridofidine
EP2857033A4 (en) PEPTIDE WITH SKIN PERMEATION
ZA201406082B (en) Use of ccr3-inhibitors
GB201111183D0 (en) Peptide
GB201208293D0 (en) Hydrochlorice salt of peptide
GB201501016D0 (en) Preparation of 18F-fluciclovine
PL2840907T3 (pl) Substytut soli
ZA201503127B (en) Peptides
GB201200555D0 (en) Peptide
IL239281A0 (en) Dihydrochloride salt of cubicistat
GB201204868D0 (en) Peptides
GB201223114D0 (en) Novel peptide
EP2891663A4 (en) PEPTIDE DERIVED FROM PSF1
GB201213672D0 (en) Protein
GB201221414D0 (en) Trans-locating peptide
GB201200623D0 (en) Peptide
GB201200624D0 (en) Peptide
ZA201308872B (en) Use of a dinitromethane salt
GB201220328D0 (en) Peptides
GB201211740D0 (en) Peptides
GB201207895D0 (en) Peptides
GB201200509D0 (en) Peptides
GB201111469D0 (en) Detection of diagnstic peptides

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)